NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/05	05 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/06/03	21 : 01	PR Newswire (US)	Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/06/03	20 : 35	PR Newswire (US)	Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/06/03	20 : 30	PR Newswire (US)	Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/31	05 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/30	05 : 53	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/30	05 : 01	PR Newswire (US)	Neurocrine Biosciences to Participate at Investor Conferences in June	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/29	05 : 14	PR Newswire (US)	Neurocrine Biosciences Announces CEO Succession Plan	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/28	21 : 30	PR Newswire (US)	Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07 : 51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07 : 34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07 : 21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	06 : 59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	05 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05 : 57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05 : 51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05 : 46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05 : 05	PR Newswire (US)	Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05 : 32	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05 : 31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05 : 31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc